Table 1Inclusion criteria

Intervention(s)Pharmalgen® for the treatment of bee and wasp venom allergy,
Population(s)People with a history of type 1 IgE-mediated systemic allergic reactions to: wasp venom and/or bee venom
ComparatorsAlternative treatment options available in the NHS, without venom immunotherapy including:
  • advice on the avoidance of bee and wasp venom,
  • high-dose antihistamines,
  • adrenaline auto-injector prescription and training
Study designRandomised controlled trials
Systematic reviews
OutcomesOutcome measures to be considered include:
Other considerationsIf the evidence allows, considerations will be given to subgroups of people, according to their:
  • risk of future stings (as determined, for example, by occupational exposure)
  • risk of severe allergic reactions to future stings (as determined by such factors as baseline tryptase levels and co-morbidities)
  • If the evidence allows, the appraisal will consider separately people who have a contraindication to adrenaline.
  • If the evidence allows, the appraisal will consider children separately.

From: Appendix 7, Project protocol

Cover of A Systematic Review of the Clinical Effectiveness and Cost-Effectiveness of Pharmalgen® for the Treatment of Bee and Wasp Venom Allergy
A Systematic Review of the Clinical Effectiveness and Cost-Effectiveness of Pharmalgen® for the Treatment of Bee and Wasp Venom Allergy.
Health Technology Assessment, No. 16.12.
Hockenhull J, Elremeli M, Cherry MG, et al.
Southampton (UK): NIHR Journals Library; 2012 Mar.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.